Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
News provided by
Share this article
Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019
(4)
Fourth quarter 2020 EYLEA
® U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and full year 2020 EYLEA U.S. net sales increased 7% versus 2019
Fourth quarter 2020 Dupixent
(2)
, which are recorded by Sanofi, increased 56% to $1.17 billion versus fourth quarter 2019 and full year 2020 Dupixent global net sales increased 75% versus 2019
Fourth quarter 2020 GAAP diluted EPS was $10.24 and non-GAAP diluted EPS
(1)
™ antibody cocktail for COVID-19 received FDA Emergency Use Authorization; new agreement signed with U.S. government to purchase up to 1.25 million additional doses
Explainer: Main findings so far of all 3 phases of Sputnik V testing Getty Images The first registered Russian vaccine has been shown to be effective, according to scientific journal The Lancet. We briefly recap what the tests did and did not confirm.
The Gamaleya Institute, producer of the first officially registered coronavirus vaccine, has finally published the results of all three phases of clinical trials in the respected medical journal
The Lancet. A total of 19,866 volunteers took part in the study. A mass Sputnik V vaccination program is already underway in Russia, with 15 other countries set to follow. Here’s what we know for sure about the vaccine as of today:
Sputnik V demonstrates 91.6% efficacy in Phase 3 trials - publication in The Lancet
MOSCOW. Feb 2 (Interfax) - Russia s Sputnik V coronavirus vaccine has demonstrated 91.6% efficacy in Phase 3 clinical trials, the Russian Direct Investment Fund (RDIF) said with the reference to the publication in The Lancet. Sputnik V s efficacy in fighting Covid-19 is validated by internationally peer reviewed data published in The Lancet. Efficacy of Sputnik V against Covid-19 was reported at 91.6%, RDIF said in a statement on Tuesday.
Data on 19,866 volunteers (14,954 of whom received the vaccine and 4,902 the placebo) was analyzed. The calculation is based on the analysis of 78 confirmed cases of Covid-19 (including 62 cases in the placebo group), it said.
<div class="at-above-post addthis tool" data-url="https://www.metro.us/chinas-cansino-says-gets/"></div>(Reuters) – China’s CanSino Biologics Inc said on Monday an independent committee found the drugmaker’s COVID-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of Phase 3 trial data. No adverse events related to the vaccine had occurred and the findings of the Independent Data Monitoring Committee (IDMC) meant the […]<! AddThis Advanced Settings above via filter on get the excerpt ><! AddThis Advanced Settings below via filter on get the excerpt ><! AddThis Advanced Settings generic via filter on get the excerpt ><! AddThis Share Buttons above via filter on get the excerpt ><! AddThis Share Buttons below via filter on get the excerpt ><div class="at-below-post addthis tool" data-url="https://www.metro.us/chinas-cansino-says-ge
Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA s cancer alliance pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.